Peplin into Phase III

By Dylan Bushell-Embling
Tuesday, 09 September, 2008

Peplin [ASX: PLI] has begun a Phase III trial of its PEP005 gel for solar keratoses, common pre-cancerous skin lesions.

The trial will examine the efficacy of the gel when applied to locations other than the head. It will be simultaneously conducted in sites in Australia and the US.

The trial is being conducted with a Special Protocol Assessment from the US FDA, which ensures that the results of the study may be submitted to the FDA as part of the basis of a new drug application.

Around 250 participants are expected take part in the trial of PEP005, an ingenol mebutate gel.

Related News

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...

Maternal cannabis use puts kids at risk of behavioural problems

Children exposed to their mother's cannabis use during pregnancy and after birth are three...

Over-the-counter pain relievers may improve concussion recovery

People who take over-the-counter pain relievers after a concussion may recover faster than those...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd